Barhemsys

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• The recommended dosage of BARHEMSYS:
• Prevention of PONV, either alone or in combination with another antiemetic :
• 5 mg as a single intravenous dose infused over 1 to 2 minutes at the time of induction of anesthesia.
• ( 2.1 ) Treatment of PONV :
• 10 mg as a single intravenous dose infused over 1 to 2 minutes in the event of nausea and/or vomiting after a surgical procedure.
• ( 2.1 ) See full prescribing information for preparation and administration instructions .
• ( 2.2 )
• 2.1 Recommended Dosage The recommended adult dosage of BARHEMSYS and infusion rate by indication is shown in the table below:
• Indication Adult Dosage Regimen Prevention of PONV 5 mg as a single intravenous injection infused over 1 to 2 minutes at the time of induction of anesthesia [see Dosage and Administration (2.2) ] .
• Treatment of PONV 10 mg as a single intravenous injection infused over 1 to 2 minutes in the event of nausea and/or vomiting after a surgical procedure [see Dosage and Administration (2.2) ] .
• 2.2 Preparation and Administration Dilution of BARHEMSYS is not required before administration.
• BARHEMSYS is chemically and physically compatible with Water for Injection, 5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer's Solution (also known as Ringer's Lactate Solution, Compound Sodium Lactate Solution, and Hartmann's Solution), any of which may be used to flush an intravenous line before or after administration of BARHEMSYS.
• Protect from light.
• BARHEMSYS is subject to photodegradation.
• Administer BARHEMSYS within 12 hours of removal of the vial from the protective carton.
• Prior to administration, inspect the BARHEMSYS solution visually for particulate matter and discoloration.
• Discard if particulate matter or discoloration is observed.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

Safety and effectiveness in pediatric patients have not been established.

Quoted from the official label, section “Pediatric Use”.

Use in older people

• Of the total number of patients enrolled in controlled clinical trials who received BARHEMSYS 5 mg for prevention of PONV or 10 mg for treatment of PONV, 235 (17%) were 65 years of age and older, while 59 (4%) were 75 years of age and older.
• No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Quoted from the official label, section “Geriatric Use”.

Side effects

• Most common adverse reactions (≥ 2%) are:
• Prevention of PONV :
• increased blood prolactin concentrations, chills, hypokalemia, procedural hypotension, and abdominal distension.
• ( 6.1 ) Treatment of PONV : infusion site pain.
• ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Acacia Pharma at 1-877-357-9237 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
• 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
• The data described below reflect exposure to BARHEMSYS in 1,166 patients treated in placebo-controlled trials. 748 of these patients received a dose of 5 mg for prevention of PONV (of whom 572 received another antiemetic concomitantly) and 418 patients received 10 mg for treatment of PONV [see Clinical Studies (14.1 , 14.2) ] .
• The mean age of the population was 49 years (range 18 to 91 years), 87% female, 80% White/Caucasian, 9% Black, and 1% Asian.
• Prevention of PONV Common adverse reactions reported in at least 2% of adult patients who received BARHEMSYS 5 mg and at a higher rate than placebo in Studies 1 and 2 for the prevention of PONV are shown in Table 1.
• Table 1.
• Common Adverse Reactions Reported in at least 2% of patients treated with BARHEMSYS and at a higher rate than placebo in Adult Patients in Studies 1 and 2 of BARHEMSYS for Prevention of PONV BARHEMSYS 5 mg Placebo N=748 N=741 Chills 4% 3% Hypokalemia 4% 2% Procedural hypotension 3% 2% Abdominal distension 2% 1% Serum prolactin concentrations were measured in Study 1 where 5% (9/176) of BARHEMSYS-treated patients vs 1% (1/166) of placebo-treated patients had increased blood prolactin reported as an adverse reaction.
• Serum prolactin concentrations increased from a mean of 10 ng/mL at baseline to 32 ng/mL after BARHEMSYS treatment in 112 females (upper limit of normal 29 ng/mL) and from 10 ng/mL to 19 ng/mL in 61 males (upper limit of normal 18 ng/mL).
• No clinical consequences due to elevated prolactin levels were reported.
• Treatment of PONV The most common adverse reaction, reported in at least 2% of adult patients who received BARHEMSYS 10 mg (N=418) and at a higher rate than placebo (N=416), in clinical trials for the treatment of PONV (Studies 3 and 4) was infusion site pain (BARHEMSYS 6%; placebo 4%).
• 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval chronic oral use of amisulpride outside of the United States (BARHEMSYS is not approved for oral dosing or chronic use).
• Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
• Blood and lymphatic system disorders :
• agranulocytosis Cardiac disorders :
• bradycardia, torsades de pointes, ventricular tachycardia, prolonged QT by electrocardiogram General disorders :
• neuroleptic malignant syndrome Immune system disorders :
• angioedema, hypersensitivity, urticaria Hepatic disorders :
• increased hepatic enzymes Nervous system disorders :
• agitation, anxiety, dystonia, extrapyramidal disorder, seizure Psychiatric disorders :
• confusional state, insomnia, somnolence Vascular disorders :
• hypotension

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• QT Prolongation Instruct patients to contact their healthcare provider immediately if they perceive a change in their heart rate, if they feel lightheaded, or if they have a syncopal episode [see Warnings and Precautions (5.1) ] .
• Drug Interactions Advise patients to report to their healthcare provider if they are taking drugs which prolong the QT interval [see Warnings and Precautions (5.1) ].
• Lactation Women may consider reducing infant exposure through pumping and discarding breastmilk for 48 hours after BARHEMSYS administration [see Use in Specific Populations (8.2) ] .

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS Injection:
• 5 mg/2 mL (2.5 mg/mL) or 10 mg/4 mL (2.5 mg/mL) as a clear, colorless sterile solution in a single-dose vial. Injection:
• 5 mg/2 mL (2.5 mg/mL) or 10 mg/4 mL (2.5 mg/mL) in a single-dose vial. ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• BARHEMSYS (amisulpride) injection is supplied as follows:
• NDC 71390-125-20:
• Package of 10 cartons.
• Each carton (NDC 71390-125-21) contains one single-dose vial of clear, colorless, sterile solution of BARHEMSYS (amisulpride) injection, 5 mg in 2 mL (2.5 mg/mL).
• NDC 71390-125-50: Package of 10 cartons.
• Each carton (NDC 71390-125-51) contains one single-dose vial of clear, colorless, sterile solution of BARHEMSYS (amisulpride) injection, 10 mg in 4 mL (2.5 mg/mL).
• Store vials at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
• Protect from light.
• Administer BARHEMSYS within 12 hours after the vial is removed from the protective carton [see Dosage and Administration (2.2) ] .

Quoted from the official label, section “How Supplied”.

How to store it

Store vials at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from light. Administer BARHEMSYS within 12 hours after the vial is removed from the protective carton [see Dosage and Administration (2.2) ] .

Quoted from the official label, section “Storage and Handling”.

What is in it

• The active ingredient of BARHEMSYS is amisulpride, a dopamine-2 (D 2 ) receptor antagonist.
• Its chemical name is 4-Amino- N -[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)- o -anisamide.
• It has the following chemical structure:
• (racemic) The empirical formula is C 17 H 27 N 3 O 4 S representing a molecular weight of 369.48.
• Amisulpride is a white or almost white crystalline powder.
• It is practically insoluble in water, sparingly soluble in ethanol and freely soluble in methylene chloride, and has a melting point of around 126°C.
• The compound is racemic and shows no optical rotation and is not hygroscopic.
• No other polymorphs of amisulpride have been reported.
• BARHEMSYS (amisulpride) injection is a clear, colorless, nonpyrogenic, sterile solution formulation of amisulpride 5 mg/2 mL (2.5 mg/mL) or 10 mg/4 mL (2.5 mg/mL) for intravenous infusion presented in a single-dose vial.
• It has a pH of approximately 5.0 and the osmolality of the product is between 250 and 330 mOsmol/kg.
• Each 2 mL vial of BARHEMSYS contains 5 mg of amisulpride; 18.7 mg of citric acid monohydrate USP; 3.6 mg of sodium chloride USP; 32.64 mg of trisodium citrate dihydrate; hydrochloric acid NF and sodium hydroxide NF as needed to adjust the pH (4.75 to 5.25); and Water for Injection USP to make up to volume.
• Each 4 mL vial of BARHEMSYS contains 10 mg of amisulpride; 37.4 mg of citric acid monohydrate USP; 7.2 mg of sodium chloride USP; 65.3 mg of trisodium citrate dihydrate; hydrochloric acid NF and sodium hydroxide NF as needed to adjust the pH (4.75 to 5.25); and Water for Injection USP to make up to volume.
• Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page